Wulyo Rajabto Vitya Chandika Agnes Stephanie Harahap Maria Francisca Ham
10.2147/IMCRJ.S348718
Int Med Case Rep J
2022 Jun 1;15:269-273.
covid-19 brentuximab vedotin monotherapy refractory hodgkin’s lymphoma
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/35677855/
Case Reports
PMC9167837
35677855
The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
2022